VCNXOTCPharmaceutical PreparationsFiscal year ends December 31

VACCINEX, INC.

Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025

$1.00−0.01 (-0.99%)

Close on Oct 19, 2026

Market cap: $3.22M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Dec 31, 2024

Total debt

$25.00K

$25.00K due within a year

Net debt

-$1.08M

After $1.11M of cash

Implied interest rate

3.17%

FY2024 interest ÷ average debt

Interest coverage

-9367.5×

FY2024 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Vaccinex's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Vaccinex's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-14 reverse split on Apr 2, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VCNX.

Revenue growth5.4% · median -15.1%

Operating margin-3117.3% · median -6620.5%

Net margin-3100.5% · median -523.2%

Company	Revenue	Growth
RLYB	$646.00K	-15.1%
VCNX	$601.00K	+5.4%
YARW	$476.00K	-2.1%
GOVX	$0	-100.0%
ERNA	–	–
ANIX	–	–

Company

Exchange: OTC
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 23
Held by institutions: 0.0%
Auditor: Deloitte & Touche LLP
SEC CIK: 1205922

Advertisement
300 × 250